Utilization and medical care expenditures in patients with chronic obstructive pulmonary disease: A managed care claims data analysis

Disease Management and Health Outcomes

Volumn 13, Issue 6, 2005, Pages 405-412

  Yu Isenberg, Kristina S ^a   Vanderplas, Ann ^a,c   Chang, Eunice Y ^a   Shah, Hemal ^b  

^a Prescription Solutions   (United States)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; THEOPHYLLINE;

ADULT; AGED; ARTICLE; BREATHING; CALCULATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; COMORBIDITY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DEMOGRAPHY; EARLY DIAGNOSIS; EMERGENCY WARD; FEMALE; FINANCIAL MANAGEMENT; GROUPS BY AGE; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HEALTH SERVICE; HOSPITAL ADMISSION; HOSPITAL CHARGE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MEDICAL CARE; OUTPATIENT; PHARMACEUTICAL CARE; PHYSICIAN; PRESCRIPTION; PRIMARY MEDICAL CARE; QUALITY OF LIFE; RETROSPECTIVE STUDY;

EID: 28944432577     PISSN: 11738790     EISSN: 11738790     Source Type: Journal    
DOI: 10.2165/00115677-200513060-00005     Document Type: Article

References (21)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD), World Health Organization (WHO), National Heart, Lung and Blood Institute (NHBLI). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Bethesda, MD: GOLD, WHO, NHBLI; 2004. Available from URL: http://www.goldcopd.org/goldwr2004clean.pdf [Accessed 2005 Feb 13]
2. Mannino DM. COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest 2002; 121 (5 Suppl.): 121S-6S
3. Mannino DM, Homa DM, Akinbami LJ et al. Chronic obstructive pulmonary disease surveillance - United States, 1971-2000. Morbid Mortal Wkly Rep 2002; 51 (SS06): 1-16
4. Hurd SS. International efforts directed at attacking the problem of COPD. Chest 2000; 117 (5): 336S-8S
5. Strategies in preserving lung health and preventing COPD and associated diseases. The National Lung Health Education Program (NLHEP). Chest 1998; 113 (2 Suppl.): 123S-63S
6. National Heart, Lung, and Blood Institute. Morbidity and mortality: 2002 chart book on cardiovascular, lung, and blood diseases. Bethesda, MD: National Heart, Lung, and Blood Institute, 2002
7. Connors AF, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. Am J Respir Crit Care Med 1996; 154: 959-67
8. Regueiro CR, Hamel MB, Davis RB, et al. A comparison of generalist and pulmonologist care for patients hospitalized with severe chronic obstructive pulmonary disease: resource intensity, hospital costs, and survival. Am J Med 1998; 105: 366-72
9. Grasso ME, Weller WE, Shaffer TJ, et al. Capitation, managed care, and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 158: 133-8
10. Cydulka RK, McFaden Jr ER, Everman CL, et al. Patterns of hospitalization in elderly patients with asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997; 156: 1807-12
11. Melikian C, White TJ, Vanderplas A, et al. Adherences to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy combination therapy, and fixed dose combination therapy. Clin Ther 2002; 3: 460-7
12. White TJ, Chang E, Leslie S, et al. Patient adherence with HMG reductase inhibitor therapy among two types of prescription services. J Manag Care Pharm 2002; 8 (3): 186-91
13. Chen K, White TJ, Juzba M, et al. Oral Isotretinoin: an analysis of its utilization from a managed care perspective. J Manag Care Pharm 2002; 8 (4): 272-7
14. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152: S77-S121
15. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9CM administrative databases. J Clin Epidemiol 1992; 45 (6): 613-9
16. Mapel DW, Hurley JS, Frost FJ, et al. Health care utilization in chronic obstructive pulmonary disease: a case-control study in a health maintenance organization. Arch Intern Med 2000; 160: 2653-8
17. Strassels SA, Smith DH, Sullivan SD, et al. The costs of treating COPD in the United States. Chest 2001; 119 (2): 344-52
18. Minino AM, Smith BL. Deaths: preliminary data for 2000. Natl Vital Stat Rep 2001; 49 (12): 1-40
19. Alexopoulos EC, Burdorf A. Prognostic factors for respiratory sickness absence and return to work among blue collar workers and office personnel. Occup Environ Med 2001; 58 (4): 246-52
20. Szubert Z, Szeszenia-Dabrowska N, Sobala W. Sickness absence in a rubber plant in Poland. Int J Occup Med Environ Health 1998; 11: 179-88
21. Post WK, Burdorf A, Bruggeling TG. Relations between respiratory symptoms and sickness absence among workers in the animal feed industry. Occup Environ Med 1994; 51: 440-6